On-Table Diagnosis: Brain Tumor Test Transforms Care

The NHS has implemented a rapid genomic test that drastically cuts brain tumor diagnosis time from up to eight weeks to merely two hours. This groundbreaking technology analyzes a tumor's genetic code, enabling quicker identification of its type. Such speed means patients can commence treatments, including radiotherapy and chemotherapy, significantly earlier, sparing them weeks of distressing uncertainty.

This new diagnostic approach is already benefiting patients like Steve Palmer, who received his diagnosis while surgeons operated to remove his glioblastoma. Consultant neurosurgeon Stuart Smith described the test as "almost magical," highlighting its capability to deliver full genetic analysis during surgery—a process that previously took six to eight weeks.

The test's ability to provide intraoperative results can influence surgical strategy. For curable tumors, surgeons may operate more radically, while for aggressive types, they can proceed with caution to minimize brain damage. The technology uses a sequencing machine from Oxford Nanopore and specialist software developed at the University of Nottingham.

Over 12,000 people in the UK are diagnosed with primary brain tumors annually, making it the leading cancer killer among children and adults under 40. The NHS England pilot is being rolled out in five specialist centers, with plans for further expansion. This initiative aims to establish rapid genomic testing as a routine part of NHS care nationwide, ensuring faster, more precise diagnoses for all.

Prof. Frankie Swords, NHS medical director, stated the test has the potential to transform brain tumor diagnosis, with results delivered in days rather than weeks. This faster diagnosis allows patients quicker access to appropriate treatment and clinical trials, and can empower surgeons with critical information at the operating table.